[Prognostic factors of endocervical type adenocarcinoma in uterine cervix].
Adenocarcinoma of the uterine cervix accounts for an increasing percentage of cervical cancers with controversial clinical problems. Three hundred and thirty-seven cases of endocervical type, adenocarcinoma cases were treated at the Cancer Institute Hospital between 1950 and 1984. Of the many clinicopathologic variables evaluated for prognosis, the following were significant. (1) Clinical Stage: Five and 10 year survival in each stage was: 83.3% and 78.0% (stage I), 71.6% and 55.8% (stage II) and 27.1% and 19.7% (stage III), respectively (p < 0.01, < 0.05). (2) Myometrial invasion: One hundred and forty stage Ib.II patients were operated on and then separated into 3 groups according to the degree of myometrial invasion. Five and 10 year survival in the "< 1/3" group was 92.7% and 86.9%, the "1/3-2/3" group 86.6% and 82.3% and the "> 2/3" group 75.0% and 63.2%, respectively. There was a significant difference between the "< 1/3" and "1/3-2/3" groups and the "> 2/3" group (p < 0.05). (3) Pelvic lymph node metastasis: Five and 10 year survival in negative cases of pelvic lymph node metastasis was 90.7% and 85.8%, compared with 40.9% and 29.8% in positive cases (p < 0.05). (4) Cardinal invasion: Minimal 5 year survival for negative cases was 71.2%, compared with 11.1% for positive cases (p < 0.001). (5) Surgical therapy for early stage cancer: Minimal 5 year survival for operated cases was 81.3%, compared with 58.5% for irradiated cases (p < 0.01).
Department of Gynecology, Cancer Institute Hospital, Tokyo.
K
K
Yokosuka
K
K
Hasumi
D000230:Adenocarcinoma / Q000401:mortality*; D005260:Female; D006801:Humans; D008207:Lymphatic Metastasis; D008875:Middle Aged; D009361:Neoplasm Invasiveness; D009367:Neoplasm Staging; D010388:Pelvis; D011379:Prognosis; D012189:Retrospective Studies; D015996:Survival Rate; D002583:Uterine Cervical Neoplasms / Q000401:mortality* / Q000473:pathology